Trial · NCT00523341
Results by group402
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 402
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | Any adverse event (AE) | 2070 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | Any adverse event (AE) | 2173 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | Serious adverse event | 945 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | Serious adverse event | 1014 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | Fatal adverse event | 101 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | Fatal adverse event | 108 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | AE leading to study discontinuation | 145 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | AE leading to study discontinuation | 173 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | AE leading to discontinuation of denosumab | 184 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | AE leading to discontinuation of denosumab | 216 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | Treatment-related adverse events (TRAE) | 185 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | Treatment-related adverse events (TRAE) | 188 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | Serious treatment-related adverse events | 26 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | Serious treatment-related adverse events | 28 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | Fatal treatment-related adverse events | 1 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | Fatal treatment-related adverse events | 0 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | TRAE leading to study discontinuation | 16 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | TRAE leading to study discontinuation | 9 | participants | |
| Number of Participants With Adverse Events (AEs) | Placebo / Denosumab | TRAE leading to discontinuation of denosumab | 30 | participants | |
| Number of Participants With Adverse Events (AEs) | Denosumab / Denosumab | TRAE leading to discontinuation of denosumab | 25 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00523341/results